(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
8 May 2014 (08.05.2014)

WIPO | PCT

(10) International Publication Number
WO 2014/070939 A1

(51) International Patent Classification:
C07K 16/40 (2006.01)

(21) International Application Number:
PCT/US2013/067591

(22) International Filing Date:
30 October 2013 (30.10.2013)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/720,350 30 October 2012 (30.10.2012) US
61/724,858 9 November 2012 (09.11.2012) US

(71) Applicant: **GILEAD SCIENCES, INC.** [US/US]; 333 Lakeside Drive, Foster City, California 94404 (US).

(72) Inventors: **BORNSTEIN, Jeffrey D.**; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404 (US). **ADAMKEWICZ, Joanne I.**; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404 (US). **SMITH, Victoria**; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404 (US). **LYMAN, Susan K.**; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404 (US). **CHIEN, Jason**; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404 (US). **LI, Xiaoming**; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404 (US). **SHAO, Lixin**; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404 (US).

(74) Agents: **MASHRUWALA, Mary Anne** et al.; Cooley LLP, 1299 Pennsylvania Avenue, NW, Suite 700, Washington, District of Columbia 20004 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: THERAPEUTIC AND DIAGNOSTIC METHODS RELATED TO LYSYL OXIDASE-LIKE 2 (LOXL2)




FIG. 1

(57) Abstract: Provided are therapeutic, diagnostic, and prognostic methods for disease, including diseases associated with fibrosis and cancer using agents that bind to, inhibit, and/or detect lysyl oxidase-like 2 (LOXL2), and agents, compositions, kits, assay systems, and devices for use with such methods.

WO 2014/070939 A1

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

— *with international search report (Art. 21(3))*

— *with sequence listing part of description (Rule 5.2(a))*